Want to see TECH full AI Analyst Report?
Adjusted Operating Income by Segment
Presents segment profits after removing one-time charges and accounting adjustments to reveal underlying operating performance. Helps you judge the durability of margins and whether reported improvements reflect real efficiency gains or temporary items.Diagnostics & Spatial Biology has been highly lumpy—periodic large swings and a pronounced mid‑2023 trough point to one‑off timing, product mix, or acquisition-related effects rather than steady organic growth. The past several quarters show a clearer, sustained upswing, suggesting operational normalization and reduced downside risk versus the 2023 disruption. Still, the historical volatility implies earnings remain sensitive to project timing and mix; treat short‑term quarters as noisy until management demonstrates durable margin improvements or steadier revenue drivers.
Date | Diagnostics and Spatial Biology |
|---|---|
Jun 30, 2026 | $10.07M |
Mar 31, 2026 | $10.32M |
Dec 31, 2025 | $8.43M |
Sep 30, 2025 | $8.88M |
Jun 30, 2025 | $5.38M |
Mar 31, 2025 | $8.42M |
Dec 31, 2024 | $3.24M |
Sep 30, 2024 | $4.28M |
Jun 30, 2024 | $11.36M |
Mar 31, 2024 | $8.10M |